EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
Rhea-AI Summary
EVOQ Therapeutics announced a Collaboration and License Agreement with Sanofi (NASDAQ: SNY) on October 16, 2025 to advance EVOQ's NanoDisc technology for autoimmune diseases. Under the deal, Sanofi will lead development and worldwide commercialization while EVOQ is eligible to receive over $500 million in upfront, preclinical, development and sales milestones plus tiered royalties on product sales. The NanoDisc platform aims to restore immune tolerance across indications including celiac disease, type 1 diabetes, MOG antibody disease, rheumatoid arthritis and lupus.
The agreement pairs EVOQ's proprietary platform with Sanofi's immunology and commercial capabilities, transferring development and market responsibilities to Sanofi and establishing milestone-driven payments and royalty economics for EVOQ.
Positive
- Deal includes over $500 million in milestone payments
- Sanofi to fund development and worldwide commercialization
Negative
- EVOQ cedes development and commercialization control to Sanofi
- EVOQ payments are milestone-based and not guaranteed
News Market Reaction
On the day this news was published, SNY gained 2.17%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
EVOQ's proprietary breakthrough NanoDisc technology restores the body's natural immune tolerance pathways and opens the door for a wide range of disease-specific, curative therapies for multiple autoimmune diseases like celiac disease, type 1 diabetes, MOG (myelin oligodendrocyte glycoprotein) antibody disease, rheumatoid arthritis and lupus. Current treatments do not address the root cause of autoimmune disease which is the breakdown and failure of the body's immune tolerance systems which results in the destruction of self-tissues.
To cure autoimmune disease, immune tolerance must be restored.
"We are truly thrilled to be collaborating with Sanofi to advance our NanoDisc technology," said David Giljohann, Ph.D., Chief Executive Officer at EVOQ. Giljohann added, "Sanofi's know-how in autoimmune disease and leadership in immunology will bring clinical development expertise and commercial presence thereby making Sanofi a highly credible and attractive partner for our technology, uniquely positioned to deliver breakthrough efficacy and convenience for patients."
Under the terms of the agreement, EVOQ and Sanofi will collaborate on research activities, Sanofi will be responsible for the development and the commercialization efforts worldwide. EVOQ is eligible to receive over
About EVOQ Therapeutics
EVOQ Therapeutics is focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens and small molecules to restore immune tolerance. For more information, please visit www.evoqtherapeutics.com
EVOQ Therapeutics Contact:
Trevor Thompson
Ionic Advisors
trevor@ionicadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/evoq-therapeutics-announces-collaboration-and-license-agreement-with-sanofi-302585825.html
SOURCE EVOQ Therapeutics, Inc.
FAQ
What did EVOQ announce with Sanofi on October 16, 2025 (SNY)?
How much can EVOQ receive under the Sanofi (SNY) collaboration?
Who is responsible for clinical development and commercialization under the EVOQ–Sanofi deal?
Which autoimmune diseases does EVOQ's NanoDisc target under the Sanofi (SNY) agreement?
Will EVOQ retain commercial rights to NanoDisc products after the Sanofi deal?
Does the EVOQ–Sanofi (SNY) payment structure guarantee revenue for EVOQ?
